Review



human kinome crispr pooled library  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Addgene inc human kinome crispr pooled library
    Human Kinome Crispr Pooled Library, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 22 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+kinome+crispr+knockout+library+brunello/pmc12730985-5-8-15?v=Addgene+inc
    Average 93 stars, based on 22 article reviews
    human kinome crispr pooled library - by Bioz Stars, 2026-07
    93/100 stars

    Images



    Similar Products

    93
    Addgene inc human kinome crispr pooled library
    Human Kinome Crispr Pooled Library, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+kinome+crispr+knockout+library+brunello/pmc12730985-5-8-15?v=Addgene+inc
    Average 93 stars, based on 1 article reviews
    human kinome crispr pooled library - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    96
    Addgene inc human kinome crispr knockout library brunello
    <t>CRISPR</t> screening revealed that co‐targeting WEE1 and AKT as a potential combination strategy in ARID1A/TP53 concurrent mutant CRC. A) Schematic description of the CRISPR knockout <t>kinome</t> library screen. (B) Results of CRISPR screen in SNUC5 cells. Scatter plots present the Z‐scores of average log 2 (fold change) for MK‐1775 vs DMSO ( x ‐axis) and for ZN‐c3 vs DMSO ( y ‐axis). (C) Immunoblot analysis confirming AKT2 knockout in SNUC5 cells (n=2). (D) Dose‐response curves of SNUC5 cells, treated with MK‐1775 (left) or ZN‐c3 (right) for 5 days. The results are representative of three independent experiments, each done in triplicate. Bars represent mean ± SD. (E) Immunoblot analysis of HCT15, SNUC5, COLO205, and HRT18 cell lines treated with 0.25 or 0.5 µ m MK‐1775 (n = 2). (F) GDSC2 analysis of indicated PI3K or AKT inhibitors according to ARID1A mutation status. Data are presented as scatter plots. Mean values are indicated by red lines. * p < 0.05, ** p < 0.01 (two‐tailed Wilcoxon rank‐sum test).
    Human Kinome Crispr Knockout Library Brunello, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+kinome+crispr+knockout+library+brunello/pmc12904052-289-0-9?v=Addgene+inc
    Average 96 stars, based on 1 article reviews
    human kinome crispr knockout library brunello - by Bioz Stars, 2026-07
    96/100 stars
      Buy from Supplier

    93
    Addgene inc human kinome
    <t>CRISPR</t> screening revealed that co‐targeting WEE1 and AKT as a potential combination strategy in ARID1A/TP53 concurrent mutant CRC. A) Schematic description of the CRISPR knockout <t>kinome</t> library screen. (B) Results of CRISPR screen in SNUC5 cells. Scatter plots present the Z‐scores of average log 2 (fold change) for MK‐1775 vs DMSO ( x ‐axis) and for ZN‐c3 vs DMSO ( y ‐axis). (C) Immunoblot analysis confirming AKT2 knockout in SNUC5 cells (n=2). (D) Dose‐response curves of SNUC5 cells, treated with MK‐1775 (left) or ZN‐c3 (right) for 5 days. The results are representative of three independent experiments, each done in triplicate. Bars represent mean ± SD. (E) Immunoblot analysis of HCT15, SNUC5, COLO205, and HRT18 cell lines treated with 0.25 or 0.5 µ m MK‐1775 (n = 2). (F) GDSC2 analysis of indicated PI3K or AKT inhibitors according to ARID1A mutation status. Data are presented as scatter plots. Mean values are indicated by red lines. * p < 0.05, ** p < 0.01 (two‐tailed Wilcoxon rank‐sum test).
    Human Kinome, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+kinome+crispr+knockout+library+brunello/pm40637801-243-5-17?v=Addgene+inc
    Average 93 stars, based on 1 article reviews
    human kinome - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    Addgene inc mdia1
    <t>CRISPR</t> screening revealed that co‐targeting WEE1 and AKT as a potential combination strategy in ARID1A/TP53 concurrent mutant CRC. A) Schematic description of the CRISPR knockout <t>kinome</t> library screen. (B) Results of CRISPR screen in SNUC5 cells. Scatter plots present the Z‐scores of average log 2 (fold change) for MK‐1775 vs DMSO ( x ‐axis) and for ZN‐c3 vs DMSO ( y ‐axis). (C) Immunoblot analysis confirming AKT2 knockout in SNUC5 cells (n=2). (D) Dose‐response curves of SNUC5 cells, treated with MK‐1775 (left) or ZN‐c3 (right) for 5 days. The results are representative of three independent experiments, each done in triplicate. Bars represent mean ± SD. (E) Immunoblot analysis of HCT15, SNUC5, COLO205, and HRT18 cell lines treated with 0.25 or 0.5 µ m MK‐1775 (n = 2). (F) GDSC2 analysis of indicated PI3K or AKT inhibitors according to ARID1A mutation status. Data are presented as scatter plots. Mean values are indicated by red lines. * p < 0.05, ** p < 0.01 (two‐tailed Wilcoxon rank‐sum test).
    Mdia1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+kinome+crispr+knockout+library+brunello/pm40355570-395-12-33?v=Addgene+inc
    Average 93 stars, based on 1 article reviews
    mdia1 - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    Addgene inc john doench
    <t>CRISPR</t> screening revealed that co‐targeting WEE1 and AKT as a potential combination strategy in ARID1A/TP53 concurrent mutant CRC. A) Schematic description of the CRISPR knockout <t>kinome</t> library screen. (B) Results of CRISPR screen in SNUC5 cells. Scatter plots present the Z‐scores of average log 2 (fold change) for MK‐1775 vs DMSO ( x ‐axis) and for ZN‐c3 vs DMSO ( y ‐axis). (C) Immunoblot analysis confirming AKT2 knockout in SNUC5 cells (n=2). (D) Dose‐response curves of SNUC5 cells, treated with MK‐1775 (left) or ZN‐c3 (right) for 5 days. The results are representative of three independent experiments, each done in triplicate. Bars represent mean ± SD. (E) Immunoblot analysis of HCT15, SNUC5, COLO205, and HRT18 cell lines treated with 0.25 or 0.5 µ m MK‐1775 (n = 2). (F) GDSC2 analysis of indicated PI3K or AKT inhibitors according to ARID1A mutation status. Data are presented as scatter plots. Mean values are indicated by red lines. * p < 0.05, ** p < 0.01 (two‐tailed Wilcoxon rank‐sum test).
    John Doench, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+kinome+crispr+knockout+library+brunello/pm40427135-290-10-16?v=Addgene+inc
    Average 93 stars, based on 1 article reviews
    john doench - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    Image Search Results


    CRISPR screening revealed that co‐targeting WEE1 and AKT as a potential combination strategy in ARID1A/TP53 concurrent mutant CRC. A) Schematic description of the CRISPR knockout kinome library screen. (B) Results of CRISPR screen in SNUC5 cells. Scatter plots present the Z‐scores of average log 2 (fold change) for MK‐1775 vs DMSO ( x ‐axis) and for ZN‐c3 vs DMSO ( y ‐axis). (C) Immunoblot analysis confirming AKT2 knockout in SNUC5 cells (n=2). (D) Dose‐response curves of SNUC5 cells, treated with MK‐1775 (left) or ZN‐c3 (right) for 5 days. The results are representative of three independent experiments, each done in triplicate. Bars represent mean ± SD. (E) Immunoblot analysis of HCT15, SNUC5, COLO205, and HRT18 cell lines treated with 0.25 or 0.5 µ m MK‐1775 (n = 2). (F) GDSC2 analysis of indicated PI3K or AKT inhibitors according to ARID1A mutation status. Data are presented as scatter plots. Mean values are indicated by red lines. * p < 0.05, ** p < 0.01 (two‐tailed Wilcoxon rank‐sum test).

    Journal: Advanced Science

    Article Title: Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R‐Loop Accumulation and DNA Repair Deficiencies

    doi: 10.1002/advs.202512074

    Figure Lengend Snippet: CRISPR screening revealed that co‐targeting WEE1 and AKT as a potential combination strategy in ARID1A/TP53 concurrent mutant CRC. A) Schematic description of the CRISPR knockout kinome library screen. (B) Results of CRISPR screen in SNUC5 cells. Scatter plots present the Z‐scores of average log 2 (fold change) for MK‐1775 vs DMSO ( x ‐axis) and for ZN‐c3 vs DMSO ( y ‐axis). (C) Immunoblot analysis confirming AKT2 knockout in SNUC5 cells (n=2). (D) Dose‐response curves of SNUC5 cells, treated with MK‐1775 (left) or ZN‐c3 (right) for 5 days. The results are representative of three independent experiments, each done in triplicate. Bars represent mean ± SD. (E) Immunoblot analysis of HCT15, SNUC5, COLO205, and HRT18 cell lines treated with 0.25 or 0.5 µ m MK‐1775 (n = 2). (F) GDSC2 analysis of indicated PI3K or AKT inhibitors according to ARID1A mutation status. Data are presented as scatter plots. Mean values are indicated by red lines. * p < 0.05, ** p < 0.01 (two‐tailed Wilcoxon rank‐sum test).

    Article Snippet: Human kinome CRISPR knockout library (Brunello) was obtained from Addgene (#73179) and was packaged into lentivirus.

    Techniques: CRISPR, Mutagenesis, Knock-Out, Western Blot, Two Tailed Test